ALSO NOTED: Ipsen inks deal with Galderma; Amgen gains Graffinity's drug tech; and much more...

> France's Ipsen inked a licensing deal with Galderma for the anti-wrinkle therapy Dysport. Ipsen gains €10 million up front and up to €20 million in milestones. Report

> Under a new discovery pact, Amgen will gain access to Graffinity's fragment-based drug discovery technology--which uses chemical microarrays to screen for small molecule fragments that bind to a variety of drug targets. Release

> Stem cell company Cytori Therapeutics is raising $21.5 million through a stock offering. Report 

> Ireland's Azur Pharma is gaining a U.S. sales force with the acquisition of Phoenix-based Pharmelle. Report

> Akzo Nobel is proceeding with plans to sell shares in Organon. Report

> Gilead Sciences is touting the results of a mid-stage trial for an HIV candidate. Report

> ReNeuron Group announced that it has entered into a revenue-sharing agreement with the international Ludwig Institute of Cancer Research and the Dana-Farber Cancer Institute concerning research conducted by these institutions on certain gene-based somatic cell expansion technology. Release

> Avalon Pharmaceuticals has initiated the primary screening phase in its collaboration with Novartis. Release

> Renhuang Pharmaceuticals announced today its signing of a Letter of Intent to acquire a subsidiary of Yerui Pharmaceutical, Qingyang Extracting Factory. Release

And Finally… A simple breath test was able to detect three-quarters of all cases of lung cancer in a recent test, validating the approach to develop new methods to diagnose cancer. Report

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.